E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Thromboembolic, bleeding and vascular complications after transcatheter aortic valve implantation in patients using oral anticoagulants |
Tromboembolische, bloedings- en vasculaire complicaties na transcatheter aortaklepimplantatie in patiënten die orale anticoagulantia gebruiken |
|
E.1.1.1 | Medical condition in easily understood language |
Blood clot, bleeding and vascular complications after transcatheter aortic valve implantation in patients using blood thinners |
Bloedpropjes, bloedings- en vasculaire complicaties na transcatheter aortaklepimplantatie in patiënten die bloedverdunners gebruiken |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy and safety of peri-procedurally continued versus interrupted oral anticoagulants in patients undergoing transcatheter aortic valve implantations |
Bestuderen van de effectiviteit en veiligheid van gecontinueerde versus gestaakte orale anticoagulantia tijdens transcatheter aortaklepvervanging |
|
E.2.2 | Secondary objectives of the trial |
Evaluate quality of life Evaluate cost-effectiveness |
Beoordelen van kwaliteit van leven Beoordelen van kosteneffectiviteit |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Effects of periprocedural continuation versus interruption of oral anticoagulant drugs during TAVI on activation of coagulation pathways and platelets 27-10-2021 Version 1 The objectives of the research questions addressed in this sub-study are to investigate: 1.1 The association between severity of aortic valve stenosis and levels of VWF & ADAMTS13 1.2 The correction of von Willebrand multimers and levels of ADAMTS13 after TAVI 1.3 The effect of TAVI on acute activation of coagulation / fibrinolysis 1.4 The effect of TAVI on platelet activation
|
Effecten van periprocedurele voortzetting versus onderbreking van orale anticoagulantia tijdens TAVI op de activering van stollingsroutes en bloedplaatjes 27-10-2021 Versie 1 De doelstellingen van de onderzoeksvragen die in dit deelonderzoek worden behandeld, zijn het onderzoeken van: 1.1 Het verband tussen de ernst van aortaklepstenose en de niveaus van VWF en ADAMTS13 1.2 De correctie van von Willebrand-multimeren en niveaus van ADAMTS13 na TAVI 1.3 Het effect van TAVI op acute activatie van stolling/fibrinolyse 1.4 Het effect van TAVI op de activering van bloedplaatjes |
|
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, a subject must meet all of the following criteria: Planned transfemoral or transsubclavian TAVI procedure Uses oral anti-coagulation at screening Written informed consent
|
Om in aanmerking te komen voor deelname aan dit onderzoek, moet een proefpersoon aan alle volgende criteria voldoen: Geplande transfemorale of transsubclavia TAVI procedure Gebruik van orale antistolling bij screening Schriftelijk geïnformeerde toestemming gegeven |
|
E.4 | Principal exclusion criteria |
Patients at high risk for thromboembolism for who interruption of oral anticoagulants is no option, i.e.: - Mechanical heart valve - Intracardiac thrombus - < 3 months after venous thromboembolism - < 6 months after TIA/stroke in patients with atrial fibrillation
|
Patiënten met hoog risico op trombo-embolie voor wie staken van orale anticoagulantia geen optie is: - Mechanische hartklepprothese - Intracardiaal trombus - <3 maanden na veneuze thromboembolie - <6 maanden na TIA/herseninfarct bij patiënten met atriumfibrilleren
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
A composite of cardiovascular mortality, all stroke, myocardial infarction, major vascular complications and type 2-4 bleeding complications at 30 days after TAVI as defined by the VARC-3 criteria.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
30 days post procedure |
30 dagen na procedure |
|
E.5.2 | Secondary end point(s) |
- Procedure related primary endpoints at 30 days. - Procedure related bleeding complications (type 1–4 bleeding ) at 30 days as defined by the VARC-3 criteria. - Procedure related thromboembolic complications (all stroke (except haemorrhagic), TIA, myocardial infarction, systemic embolism (vascular complications: distal embolization (non-cerebral) from a vascular source)) at 30 days as defined by the VARC-3 criteria. - Thromboembolic complications (all stroke (except haemorrhagic), TIA, myocardial infarction and systemic embolism (vascular complications: distal embolization (non-cerebral) from a vascular source)) at discharge and 30 days as defined by the VARC-3 criteria. - Neurologic events (overt CNS injury, covert CNS injury, neurologic dysfunction (acutely symptomatic) without CNS injury) at discharge and 30 days as defined by the VARC-3 criteria. - Cerebrovascular events (all stroke, TIA) at discharge and 30 days as defined by the VARC-3 criteria. - All stroke at discharge and 30 days as defined by the VARC-3 criteria. - Bleeding complications (type 1–4 bleeding) at discharge and 30 days as defined by the VARC-3 criteria. - Early safety at 30 days as defined by VARC-3 criteria, freedom from: all-cause mortality, all stroke, VARC type 2–4 bleeding, major vascular, access-related, or cardiac structural complication, acute kidney injury stage 3 or 4, moderate or severe aortic regurgitation, new permanent pacemaker due to procedure related conduction abnormalities, surgery or intervention related to the device. Clinical efficacy at 30 days as defined by VARC-3 criteria, freedom from: all-cause mortality, all stroke, hospitalization for procedure- or valve related causes, KCCQ Overall Summary Score <45 or decline from baseline of >10 point. - All-cause death at discharge and 30 days. - Cardiovascular death at discharge and 30 days. - Quality of life (assessed by SF-12, KCCQ, and TASQ) at 30 days and 90 days. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Blinded endpoint assessment |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Doorgebruiken versus pauzeren van orale anticoagulantia tijdens procedure |
Continuation versus interruption of oral anticoagulants during procedure |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 24 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS of 858 patients |
LVLS van 858patiënten |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 1 |